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Abstract 
Nuclear entry of the B-myb gene product (B-Myb) is dependent on multiple nuclear localization signals (NLS’s). Mutagenesis of the putative NLS’s 
of B-Myb has identified two separate NLS’s, NLSl and NLSZ. Each of the two NLS’s is essential for eflicient nuclear targeting. NLS2 contains two 
interdependent basic domains separated by 8 intervening spacer amino acids, and both basic domains are required for nuclear entry. Thus, NLS2 
belongs to a class of bipartite NLS’s. Like the NLS’s in yeast transcription factor SWIS, NLS2 contains a putative cdc2 kinase site. However, unlike 
the case of SWIS, phosphorylation at this site did not affect the nuclear targeting of B-Myb. 
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1. Introduction 
The c-myb proto-oncogene encodes a nuclear 
phosphoprotein (c-Myb) that is mainly expressed in im- 
mature haematopoietic cell lineages (for review, see [ 121). 
c-Myb is important in the regulation of proliferation and 
differentiation of haematopoietic progenitor cells 
[3,7,15,27]. c-Myb binds to specific DNA sequences and 
functions as a transcriptional activator [ 1,16,19,20,29]. 
Three functional domains, which are responsible for 
DNA binding, transcriptional activation, and negative 
regulation, respectively, were identified in c-Myb [25]. 
Two c-myb-related genes, A-myb and B-myb, were iso- 
lated [21]. The sequences of A-myb and B-myb genes 
show extensive homology to c-myb, suggesting that both 
gene products might be important in cellular prolifera- 
tion and differentiation like c-Myb. The expression of 
the B-myb gene was observed in not only the hematopoi- 
etic cell lineage but also a variety of cells, including fi- 
broblasts [21]. In addition, the B-myb mRNA levels in- 
crease in the G, periods of the cell cycle [8,22], and are 
down-regulated during macrophage differentiation [22]. 
These results support the idea that B-Myb is also in- 
volved in the regulation of cellular proliferation and dif- 
ferentiation. Previously we showed that B-Myb acts as 
a trans-activating factor [13,17]. In contrast, it was re- 
ported that the chicken and mouse B-Myb failed to 
tvans-activate several Myb-responsive gene constructs, 
suggesting that B-Myb functions as a repressor 16,281. 
Our recent analyses to resolve this discrepancy indicate 
that B-Myb has a trans-activating capacity in a cell type- 
specific manner (data not shown). The subcellular distri- 
bution of B-Myb is mainly controlled by the central large 
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domain and C-terminal basic region [18], but the essen- 
tial regions for nuclear localization are still obscure. 
In this paper we have identified two nuclear localiza- 
tion signals (NLS’s) required for the nuclear entry of 
B-Myb and examined some characteristics of these two 
NLS’s. 
2. Materials and methods 
2.1. Preparation of a GST-B-Myb fusion protein and B-Myb-spec@ic 
polyclonal antibodies 
The Bg/I-BamHI fragment prepared from pact-B-myb [13] was sub- 
cloned into the BamHI site of the pGEX-1 vector [26], which allows the 
expression of a foreign polypeptide as a fusion protein with glutathione 
Stransferase (GST). Since the presence of the C-terminal portion of 
B-Myb interfered with the solubilization of GST-B-Myb, the C-termi- 
nal coding region was deleted as follows. The AccIII site (nucleotide 
1872; nucleotide numbers are as in [21]) was changed to a blunt end 
followed by ligation, which caused a frame shift so that a termination 
codon was introduced 6 amino acids codons past this AccIII site. The 
generated plasmid, pGST-B-MybdC, encoded a fusion protein contain- 
ing the 322-amino acids region of B-Myb (amino acids 266581). Ex- 
pression and purification of GST-B-Myb were essentially as described 
by Smith and Johnson [26] except for the induction of fusion proteins 
at 25°C overnight. An antiserum was raised in a rabbit against the 
GST-B-Myb fusion protein, and purified using affinity colums in which 
GST or GST-B-Myb was used as the ligand. 
2.2. Plasmid construction 
All plasmids designed to express mutant B-Myb proteins in cultured 
cells were generated from the B-Myb expression vector, pact-B-myb, in 
which the 5’ regulatory region of the chicken cytoplasmic p-a&n gene 
is linked to the human B-myb cDNA [13]. Oligonucleotide-directed 
mutager,esis [l l] was used to make the B-Myb mutant expression vec- 
tors. dNLS1 was generated by an in-frame deletion of nucleotides 
1358-l 378 using oligonucleotides containing sequences on either side 
of the region to be deleted. M2, M4, and dNLS2 were constructed by 
the introduction of a stop codon at nucleotides 1847, 1889, and 1817, 
respectively. To construct M6, nucleotides 1817-l 846 were deleted, and 
then the ScaI-MroI fragment (nucleotides 1656-1871) was replaced by 
the ScaI-MroI fragment of M4. dNLS1 + M2, dNLS1 + M4, 
dNLS1 + M6, and dNLS1 + 2 were generated by combination of M2, 
M4, M6, and dNLS2 with the dNLS1 mutant, respectively. To make 
the potential cdc2 kinase site mutants (S/A, S/D, and S/E), serine-577 
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(nucleotides 1856-1858) was converted into alanine, aspartic acid, and 
glutamic acid, respectively. 
2.3. DNA transfection and CAT assay 
CAT co-transfection experiments using African green monkey kid- 
ney cells (CV-I), the CAT reporter plasmid pAlOCAT6MBSI or 
pmycCAT, and the B-Myb expression vector pact-B-myb were per- 
formed as described [18,20]. 
2.4. Western blotting of B-Myb mutants and immunofluorescence studies 
Western blotting to detect B-Myb protein expressed in the trans- 
fected cells was performed by using anti-B-Myb rabbit polyclonal anti- 
bodies aB-MybAb as described [18]. The intracellular distribution of 
B-Myb was analyzed by using aB-MybAb as described [18], except hat 
cells were fixed with 3% formaldehyde and permeabilized with 0.5% 
Triton X-100. 
3. Results 
3.1. Identification of two NLS’s 
By using various deletion mutants of B-Myb, we had 
demonstrated that the C-terminal basic region (amino 
acids 564-584: termed NLS2) and the central portion 
(amino acids 373-464) are important for nuclear entry 
of B-Myb [18]. In fact a deletion of NLS2 considerably, 
but not completely, impaired nuclear uptake of B-Myb. 
To abolish the nuclear entry of B-Myb, a deletion of the 
central portion in addition to NLS2 is required. In this 
central portion, the basic region (KRQRKRR) (amino 
acids 411417: termed NLSl) is located. By the calcula- 
tions as described by Hoop and Woods [lo] and Emini 
et al. [5], both NLSl and NLS2 were predicted to be 
hydrophilic and on the surface of the molecule, suggest- 
ing that both regions are good candidates for NLS (Fig. 
1A). To examine directly whether NLSl is critical 
for nuclear entry of B-Myb, a plasmid expressing a mu- 
tant lacking only NLSl (dNLS1) was constructed 
Fig. 1. Role of two NLS’s in the nuclear import of B-Myb. (A) Sche- 
matic representation of deletion mutants. On the top, the functional 
domains are shown. The surface probability and the hydrophilic plot 
of B-Myb are also indicated. Wild-type and four deletion mutants are 
schematically shown. (B) The amino acid sequence of the region around 
two NLS’s in the various forms of B-Myb. The asterisk indicates the 
stop codon. The basic amino acids in NLSl and the potential cdc2 
kinase site within NLS2 are shown by bold letters and a box, respec- 
tively. The basic amino acids conserved in NLS2 and the NLS of 
Xenopus nucleoplasmin [24] are indicated by window letters. (C) A 
typical example of the subcellular distribution. CV-1 cells transfected 
with plasmids that express wild-type (WT) and mutant B-Myb proteins 
indicated above each column were stained with aB-MybAb and fluores- 
&n-labeled second antibody (upper panel). Cells were also viewed by 
phase-contrast microscopy (lower panel). (D) Summary of the subcellu- 
lar distribution. The transfected cells were scored by counting those in 
which immunofluorescence staining was exclusively nuclear (N), in 
which nuclear concentration was evident but where some cytoplasmic 
staining could be seen (N > C), in which immunofluorescence staining 
was observed almost equally in both nuclei and cytoplasm (N + C), and 
in which cytoplasmic staining was predominant (N < C). About 100 
cells per each construct were scored, and the bar graphs give the precen- 
tage of cells in each category. 
Y Takemoto et al. IFEBS Letters 350 (1994) 5540 
(Fig. lA,B). At the same time, this mutation was com- 
bined with the deletion mutation of NLS2 (dNLS2) to 
generate the mutant dNLS1 + 2, since a deletion of 
NLSl alone was expected to only partially affect the 
nuclear targeting of B-Myb (Fig. lA,B). The plasmids 
expressing B-Myb mutants were transfected into CV-I 
cells, and the expressed B-Myb proteins were detected by 
hydrophllls 
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Fig. 2. Effects of the NLS deletion on the tram-activating capacity of 
B-Myb. (A) tram-Activation of pAlOCAT6MBSI by B-Myb mutants. 
A mixture of 6 pg of the pAIOCAT6MBSI reporter plasmid, 6 fig of 
the eff‘fector plasmid to express various B-Myb proteins shown above 
each lane or no protein (-), and 2 pg of the internal control plasmid 
pRSV/?-gal were transfected into CV-1 cells, and the CAT activity was 
assayed for 5 h. Relative CAT activity is indicated by a bar graph, 
below. (B) tram-Activation of pmycCAT by B-Myb mutants. The CAT 
co-transfection experiments with the pmycCAT reporter plasmid were 
done as described above. The CAT activity was assayed for 5 h. 
an indirect immunofluorescence using polyclonal anti- 
bodies (aB-MybAb) (Fig. 1C). Both wild-type and M4, 
which lacked the region downstream from the C-termi- 
nal end of NLS2, were localized in the nuclei. As pre- 
dicted, a deletion of either NLSl or NLS2 partially abol- 
ished the nuclear localization of B-Myb. The population 
of cells in which dNLS1 and dNLS2 were detected pre- 
dominantly in the nuclei were 60% and 8% of the trans- 
fected cells, respectively, indicating that NLS2 contrib- 
utes more to the nuclear targeting of B-Myb than NLSl 
(Fig. 1D). Moreover, B-Myb proteins lacking both 
NLSl and NLS2 are located in both the nuclei and cyto- 
plasm in most of the transfected cells. 
To confirm the results obtained by the immunofluo- 
rescence studies, we examined the trans-activating capac- 
ities of the B-Myb mutants in the CAT co-transfection 
experiments (Fig. 2). As a reporter plasmid, both the 
artificial gene construct containing tandem repeats of 
Myb-binding site, pAlOCAT6MBS-I, (Fig. 2A), and 
pmycCAT containing the human c-myc promoter (Fig. 
2B) were used. A deletion of either NLSl or NLS2 did 
not or only partly impaired the trans-activating capacity 
with either reporter plasmid. In contrast, the mutant 
lacking both NLSl and NLS2 did not truns-activate 
pAlOCAT6MBS-I. Furthermore, with pmycCAT, the 
trans-activating capacity of dNLS1 + 2 was about l/3 of 
the wild-type. 
By analyzing the mutant proteins expressed in the 
transfected cells, we also confirmed that a deletion of 
NLS 1 and/or NLS2 did not decrease the protein stability 
(Fig. 3). These results indicate that NLSl and NLS2 are 
essential for the efficient nuclear targeting of B-Myb. 
3.2. NLS2 belongs to a class of bipartite nuclear targeting 
sequences 
NLS2 is similar to the NLS of Xenopus nucleoplasmin 
in that both consist of two basic domains separated by 
about 10 intervening spacer amino acids [24]. In the case 
of nucleoplasmin, these two basic domains are interde- 
pendent, and both of them are required for efficient nu- 
clear uptake. To analyze the role of each basic domain 
in NLS2, mutants lacking either the N-terminal (amino 
acids 564-573) or the C-terminal basic domain (amino 
acids 574587) (M2 or M6) were generated (Fig. 4A), 
and their subcellular distributions were examined as de- 
scribed above. Since a deletion of NLM alone did not 
completely impair the nuclear targeting, these deletion 
mutations were combined with a NLSl deletion to gener- 
ate the mutants dNLS 1 + M6 or dNLS 1 + M2 (Fig. 4A). 
In about 60% of the transfected cells, dNLS1 and 
dNLS1 + M4 were localized predominantly in the nu- 
clei, respectively (Fig. 4B,C). However, a removal of 
either the N- or C-terminal basic domain considerably 
abolished the nuclear entry of B-Myb, and the popula- 
tion of cells in which dNLS1 + M6 and dNLS1 + M2 
were located exclusively in the nucleus were only 35% 
and 3% of the transfected cells, respectively. Thus, both 
basic domains in NLS2 are required for nuclear target- 
ing, and the C-terminal domain appears to be more 
important. Furthermore, the transport defect of a muta- 
tion in one basic domain was amplified by a simultane- 
ous mutation in the other. Therefore, these basic do- 
mains are also interdependent, like the NLS in Xenopus 
nucleoplasmin. 
3.3. Role of potential cdc2 kinase site within NLS2 
It has been pointed out that a group of proteins includ- 
ing the Xenopus nucleoplasmin, yeast transcription fac- 
tor SWIS, and human B-Myb, contain a (putative) NLS 
123456789 
Fig. 3. Immunodetection of B-Myb mutant proteins. A mixture of 10 
pg of plasmid DNA to express various forms of B-Myb indicated above 
each lane or no protein (-, lane 1) and 2 pg of the internal control 
plasmid pRSV/3-gal DNA was transfected into CV-1 cells. The B-Myb 
proteins were detected by Western blotting with aB-MybAb. 
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Fig. 4. Role of the N- or C-terminal basic domain in NLS2. (A) The 
amino acid sequence of the NLSZ-containing region of the B-Myb 
deletion mutants. The amino acid sequence of the NLS2-containing 
region is shown as in Fig. 1B. (B) Typical immunofluorescence images 
of the NLS2 mutants. Subcellular distributions of various forms of 
B-Myb were examined as described in the legend to Fig. 1. A typical 
result for each construct is shown. (C) Summary of subcellular distribu- 
tion. The results of the experiment described above are shown as in Fig. 
2D, except that the cells corresponding to N > C and N + C are com- 
bined. 
linked to the potential cdc2 kinase site [14,24]. Interest- 
ingly, the nuclear entry of SW15 was demonstrated to be 
cell cycle regulated through the CDC28-dependent phos- 
phorylation at the sites linked to the NLS [14]. The po- 
tential cdc2 phosphorylation site in B-Myb (577SPIK) is 
within NLS2, just between the two basic domains. To 
clarify whether this site is critical for nuclear localization, 
like SW15, point mutants of this site were generated (S/A, 
S/D, and S/E) (Fig. 5A), and their subcellular distribu- 
tions were examined. All of these three mutant proteins 
were localized in nuclei, like the wild-type (data not 
shown). Therefore, to amplify the effect of these point 
mutations, they were combined with the NLSl deletion 
mutation. The dNLS1 + S/A mutant protein, in which 
Ser-577 was replaced by alanine, was transported into 
the nucleus as effectively as the dNLS1 mutant (Fig. 
5B,C). Furthermore, two mutants, dNLS1 + S/D and 
dNLS1 + S/E, also showed a subcellular distribution 
similar to dNLS1, indicating that the replacement of 
Ser-577 by aspartic or glutamic acid, of which the struc- 
ture resembles the phosphorylated form, did not affect 
the nuclear entry. 
To confirm these results, the trans-activating capaci- 
ties of the Ser-577 mutants were examined in a CAT 
co-transfection experiment (Fig. 5E). None of the three 
mutants had significantly lower trans-activating capaci- 
ties compared to the parental form dNLS1. In addition, 
the levels of these proteins expressed in transfected cells 
were similar to the dNLS1 (Fig. 5D). These results sug- 
gest that the potential cdc2 phosphorylatin site in NLS2 
does not contribute to the regulation of nuclear entry. 
A 
ANLS~ '?RPEKQIRKPGLR&KVWKSLALY~ 
ANLS~+S/A IRPEKQKRKPGLR~UVBSLALD 
ANLS~+S/D IRPEKQRRKPGLRmklVmSLALD 
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1234 5 
Fig. 5. Effects of the mutations of the potential cdc2 kinase site on the 
nuclear import of B-Myb. (A) The amino acid sequence of the potential 
cdc2 kinase site in various mutants. The amino acid sequence of the 
NLSZ-containing region is shown as in Fig. IB. The putative cdc2 
kinase site, Ser-577, was changed to alanine (S/A), aspartic acid (S/D), 
and glutamine acid (S/E), respectively. (B) Typical immunofluorescence 
images. Subcellular distributions of the mutants were examined as de- 
scribed in the legends to Fig. IC. (C) Summary of subcellular distribu- 
tion. The results of immunofluorescence staining experiments are 
shown as in Fig. 4C. (D) Immunodetection of the mutants. The B-Myb 
mutant described above each lane were detected as described in the 
legend to Fig. 3. (E) trans-Activating capacities of the cdc2 kinase site 
mutants. The CAT co-transfection experiments by using pmycCAT 
were done, and the results are indicated as described in the legend to 
Fig. 2. 
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A NLSl 
377 170 
B-Myb YRLDGHTISDLSRSSRGELIESTEVGGSGIGTPPSVL -- 
332 368 
XMybl YRLDGHmLCKGNKGELImQPQ---TAFGTPPSVL 
9.7 481 
A-Myb LVLEGKK-NTCNGGNSEAVPLTSPNI----AKFSTPPAIL 
411 455 
B-Myb KFtQRKRRVALSPVTENSTSL-SFLDSCNSLTPKSTPVKTLPFSPSQ  
369 414 
XMybl KQHKKRKITLSPVTENGGSITTSVTEANSMTPKSTPVKSLmSQ 
18.2 52. 
A-Myb RKKRJZ9RVGHSPGSELRDG---SLNDGGNMALKHTPLKTLPFSPSQ - = 
B NLSP 
631 670 
SW15 ICSGGKKYENVVIK-GRPRKDGTSSVS-NI 
153 175 
Nucleoplasmin AVKRPAATKKAGQAKKKKLDEDE 
532 554 
Nl RKRRKTEE-KDAKKSKQE 
567 
B-Myb KQI(RKPGLReVRxSLA:: 
526 
XMybl RQ~RKP---H~KVRI[SLAL5d5 
642 664 
A-Myb AYKSCKQENTASGKKVRKSLVLD 
Fig. 6. Amino acid sequence of the region containing NLS in other 
members of the myb gene family. (A) NLSI-like motif. The amino acid 
sequence of the NLSl-containing region of B-Myb is aligned with those 
containing the putative NLS of the Xenopus Myb 1 (XMybl) [2] and 
the human A-Myb (A-Myb) [21]. The potential phosphorylation sites 
by CK-II and MAP kinase are shown by an underline and a double 
underline, respectively. (B) NLS2-like motif. The typical bipartite 
NLS’s of the SW15 [14], Xenopus nucleoplasmin [24], and Nl [24] are 
indicated on the top, where the important basic residues are shown by 
bold letters. The amino acid sequences of NLS2 of B-Myb and the 
NLSZ-like motif in the Xenopus Mybl (XMybl) [2] and the human 
A-Myb (A-Myb) [21] are shown below. The basic residues conserved 
between NLS2 and the NLS of nucleoplasmin are indicated by window 
letters. The potential phosphorylation sites of cdc2 kinase are boxed. 
4. Discussion 
We have demonstrated that the nuclear entry of 
B-Myb is controlled by two NLS’s, NLSl and NLM. 
NLSl contains one basic amino acid cluster, while the 
sequence of NLS2 is bipartite, comprising two interde- 
pendent clusters of basic amino acids separated by 8 in- 
tervening spacer amino acids. NLSl- and NLS2-like se- 
quences are also found in the Xenopus B-Myb [2] and 
human A-Myb [21] (Fig. 6). 
Only in about 60% and 8% of the transfected cells were 
the mutant proteins lacking either NLSl @NLSl) or 
NLS2 (dNLS2) normally transported into the nuclei 
(Fig. ID). However, both dNLS1 and dNLS2 had the 
normal or considerably higher level trans-activating ca- 
pacity (Fig. 2). This apparent discrepancy could be due 
to many B-Myb molecules being expressed in the trans- 
fected cells. If the number of B-Myb molecules is much 
higher than that of the CAT reporter plasmid, the partial 
defect of nuclear entry of B-Myb may not reflect the 
truns-activating capacity. Furthermore, in about 40% 
and 92% of the transfected cells, dNLS1 and dNLS2 are 
localized in both the nuclei and cytoplasm, respectively 
(Fig. lD), and in these cells B-Myb localized in the nuclei 
fruns-activates the CAT expression. The dNLS 1 + 2 pro- 
teins are also located in both the nuclei and cytoplasm 
in most of the transfected cells (Fig. 1D). This may also 
explain why the mutants lacking both NLSl and NLS2 
(dNLS1 + 2) still have about l/3 of the truns-activating 
capacity of the wild-type (Fig. 2). However, we cannot 
completely exclude the possibility that an unidentified 
NLS(s) other than NLSl and NLS2 exists in B-Myb. 
It is now believed that in mammalian cells, NLS is 
recognized by specific cytoplasmic proteins (receptor) 
and transported to the nuclear pore (for review, see [4]). 
The bipartite motif, which was originally found in Xen- 
opus nucleoplasmin [24] and contains two clusters of 
basic residues eparated by a spacer segment, appears to 
be a wide-spread type of NLS. It was proposed that the 
heat shock protein Hsp70 (or Hsc70) binds to and stabi- 
lizes a locally unfolded NLS, thus presenting the NLS to 
a second receptor in an unfolded conformation [4]. 
Therefore, it is interesting to know whether NLS2 in 
B-Myb also binds to Hsp70 and whether the two NLS’s 
in B-Myb, NLSl and NLS2, interact with the same or 
different cytoplasmic receptor(s). 
The potential cdc2 kinase site adjoins NLS2. A similar 
sequence was also found in the Xenopus B-Myb (Fig. 
6B). Similar linkages between NLS and putative phos- 
phorylation sites were previously pointed out in the mul- 
tiple nuclear proteins, including SW15 ~53, and nucleo- 
plasmin. In fact, the importance of the phosphorylation 
sites linked to NLS was demonstrated in the case of 
SW15 [14]. Three serine residues within or close to the 
NLS of SW15 are phosphorylated by CDC28 kinase in 
a cell cycle-dependent manner, being phosphorylated 
when SW15 is in the cytoplasm and dephosphorylated 
when it is in the nucleus. In constrast o the case of SWIS, 
a mutation of Ser-577 to alanine, aspartic acid, or glu- 
tamic acid did not affect the nuclear importation. How- 
ever our results cannot exclude the possibility that the 
phosphorylation-dependent regulation of nuclear uptake 
is controlled by multiple phosphrylation sites, and muta- 
tion of only one site, such as Ser-577, is not sufficient to 
eliminate this regulation. In fact, in the case of SWIS, 
mutation of any one of three serine residues to alanine 
reduces but does not eliminate cell cycle-regulated nu- 
clear entry. It should be noted that multiple potential 
phosphorylation sites by casein kinase II (CK-II), cdc2 
kinase, and MAP kinase are located around NLS 1, and 
some of them are conserved in the proteins encoded by 
other members of the myb gene family, human A-Myb 
and Xenopus B-Myb (Fig. 6A). Our results also do not 
exclude the possibility that Ser-577 controls the rate of 
transport, because in our immunofluorescence studies 
the nuclear accumulation of B-Myb was examined, but 
60 
not the rate of transport. In fact, the rate of nuclear 
transport of the SV40 T antigen was demonstrated to be 
determined by the CK-II site flanking the NLS [23]. 
Therefore, more precise work is required to clarify the 
role of the potential cdc2 kinase site in B-Myb. 
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